Fed Sparks Profit T...
Health Care: Drugs
iBio Inc. (IBIO: AMEX)
$0.42 -0.01 | -2.52%
05/24/13 - 03:58 PM ET
Company Income Statement
| Jun 2012 | Jun 2011 | Jun 2010 | Jun 2009 | |
| Sales | 1.28M | 520.08K | 0.00 | 1.18M |
| Cost of Sales | 0.00 | 0.00 | -337.03K | 217.00K |
| Gross Operating Profit | 1.28M | 520.08K | 337.03K | 960.00K |
| Selling, General, and Administrative Expenses | 5.62M | 7.09M | 2.07M | 1.80M |
| Research & Development | 4.98M | 3.08M | 2.52M | 797.00K |
| Operating Income before D & A (EBITDA) | -9.33M | -9.65M | -4.25M | -1.64M |
| Depreciation & Amortization | 329.71K | 376.81K | 337.03K | 284.00K |
| Interest Income | 11.67K | 12.62K | 12.73K | 0.00 |
| Other Income - Net | 3.70M | -2.45M | -1.49M | 20.00K |
| Special Income / Charges | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Income Before Interest Expenses (EBIT) | -5.94M | -12.47M | -6.06M | -1.91M |
| Interest Expense | 62.85K | 50.50K | 13.11K | 0.00 |
| Pre-Tax Income | -6.01M | -12.52M | -6.08M | -1.91M |
| Income Taxes | 0.00 | 0.00 | 2.40K | 2.00K |
| Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Income From Continuing Operations | -5.68M | -12.14M | -6.08M | -1.91M |
| Net Income From Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Income From Total Operations | -5.68M | -12.14M | -6.08M | -1.91M |
| Extraordinary Income/Losses | 0.00 | 0.00 | 0.00 | 0.00 |
| Income From Cum. Effect of Acct. Change | 0.00 | 0.00 | 0.00 | 0.00 |
| Income From Tax Loss Carryforward | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Gains / Losses | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Net Income | -5.68M | -12.14M | -6.08M | -1.91M |
| Normalized Income (Net Income From Continuing Operations, Ex. Special Income / Charge) |
-5.68M | -12.14M | -6.08M | -1.91M |
| Preferred Dividends | ||||
|---|---|---|---|---|
| Net Income Available To Common | -5.68M | -12.14M | -6.08M | -1.91M |
| Basic EPS from Continuing Ops. | -0.14 | -0.39 | -0.22 | -0.09 |
| Basic EPS from Discontinued Ops. | 0.00 | 0.00 | 0.00 | 0.00 |
| Basic EPS from Total Operations | -0.14 | -0.39 | -0.22 | -0.09 |
| Basic EPS from Extraordinary Inc. | 0.00 | 0.00 | 0.00 | 0.00 |
| Basic EPS from Cum Effect of Accounting Change | 0.00 | 0.00 | 0.00 | 0.00 |
| Basic EPS from Tax Loss Carryf'd. | 0.00 | 0.00 | 0.00 | 0.00 |
| Basic EPS from Other Gains (Losses) | 0.00 | 0.00 | 0.00 | 0.00 |
| Basic EPS, Total | -0.14 | -0.39 | -0.22 | -0.09 |
| Basic Normalized Net Income/Share | -0.14 | -0.39 | -0.22 | -0.09 |
| EPS fr Continuing Ops. | -0.14 | -0.39 | -0.22 | -0.09 |
| EPS fr Discontinued Ops | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS fr Total Ops. | -0.14 | -0.39 | -0.22 | -0.09 |
| EPS fr Extraord. Inc. | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS fr Cum Effect of Accounting Change | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS fr Tax Loss Carfd. | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS fr Other Gains (L) | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS, Total | -0.14 | -0.39 | -0.22 | -0.09 |
| Diluted Normalized Net Inc/Shr (Net Income From Continuing Operations, Ex. Special Income / Charge) |
-0.14 | -0.39 | -0.22 | -0.09 |
| Dividends Paid per Share | 0.00 | 0.00 | 0.00 | 0.00 |
Portfolios with IBIO
- Portfolio NameUser Type
- Usercosmo
- ContributorStocks Under-$10 Moving Hig...
- ContributorStocks Under-$10 Setting Up...
- UserBiotech88
Latest IBIO Headlines from TheStreet
- 4 Biotech Stocks Under $10 Moving Higher 10.05.12 | 08:10 am
- 5 Stocks Under $10 Setting Up to Break Out 09.13.12 | 12:09 pm
- 10 New Stocks Rated by TheStreet 08.03.11 | 02:08 pm
Press Releases for IBIO
- GE Alliance Awarded Contract To Design New Plant-based Manufacturing Facility In Brazil - PR Newswire 04.09.13 | 07:04 am
- IBio Selects Proprietary Recombinant C1 Inhibitor For Clinical Development - PR Newswire 03.26.13 | 07:03 am
- IBio Adds To IBioModulator Portfolio And Product Pipeline - PR Newswire 03.13.13 | 07:03 am
- IBio Adds New Therapeutic Antibody To Its Pipeline - PR Newswire 03.04.13 | 09:03 am
- IBio, Inc. Receives Anticipated Notice From NYSE MKT That Company Is Below Certain Continued Listing Standards - PR Newswire 03.04.13 | 09:03 am
- IBio And Caliber Biotherapeutics Establish License And Collaboration Relationship - PR Newswire 02.19.13 | 07:02 am
- IBio, Inc. Receives Approval From NYSE MKT Of Compliance Plan - PR Newswire 02.13.13 | 07:02 am
- IBio Announces At-the-Market Equity Offering - PR Newswire 02.01.13 | 09:02 am
- IBio Announces New Appointment To Board Of Directors And New Addition To Executive Management Team - PR Newswire 12.21.12 | 07:12 am
- National Institute Of Health Awards Contract To Support Use Of IBio's Proprietary Technology For Improved Anthrax Vaccine - PR Newswire 12.05.12 | 07:12 am
Partner Headlines for IBIO
- Under Construction Rehash: Buy Acadia And Astex - Seeking Alpha 09.20.12 | 09:09 am
- Rituxan And Its Biosimilar Competitors - Seeking Alpha 07.30.12 | 09:07 am
- iBio Announces Proposed Public Offering; No Amount Given - Benzinga 01.09.12 | 04:01 pm
- IBIO: Pharma Stock With Much Downside Risk And Low Upside Potential - Seeking Alpha 11.02.11 | 08:11 am
- iBio Still Overvalued; More Dilution Likely - Seeking Alpha 06.29.11 | 09:06 am
- Trading Resumes: iBio, Inc. - Benzinga 03.08.11 | 01:03 pm
- iBio Overvalued - Seeking Alpha 02.09.11 | 08:02 am
- 4 Stocks for the Aggressive Investor - Seeking Alpha 02.02.11 | 08:02 am
- iBio: A True Paradigm Shift - Seeking Alpha 01.24.11 | 09:01 am
